Preserving renal function in adults with hypertension and diabetes: a consensus approach

Author(s): Bakris GL, Williams M, Dworkin L, Elliott WJ, Epstein M, et al.


Over 11 million Americans have both diabetes and hypertension-comorbid diseases that strongly predispose people to both renal as well as cardiovascular (CV) injury. Hypertension substantially contributes to CV morbidity and mortality in people with diabetes. Diabetes is the most common cause of end-stage renal disease in the United States. Furthermore, hypertension and diabetes are particularly prevalent in certain populations, such as African-Americans and Native Americans. Since the 1994 Working Group Report on Hypertension and Diabetes, a large body of clinical trial data has affirmed the original blood pressure goal of less than 130/85 mmHg recommended to preserve renal function and reduce CV events in people with hypertension and diabetes. Data that are more recent have emerged, however, to support an even lower diastolic blood pressure goal, ie, 80 mmHg, in order to optimally preserve renal function and reduce CV events in people with diabetic nephropathy. A review of clinical trials indicates that more than 65% of people with diabetes and hypertension will require two or more different antihypertensive medications to achieve the new suggested target blood pressure of 130/80 mmHg. The purpose of this report is to update the previous recommendations with a focus on level of blood pressure control, proteinuria reduction, and therapeutic approaches to achieve these goals. We provide an evidence-based approach, integrating data from the major clinical trials that were designed as randomized prospective, long-term studies that had as a primary endpoint either progression of diabetic nephropathy or reduction in CV events. This report also addresses socioeconomic and cultural barriers that hinder achievement of blood pressure goals. Lastly, the report discusses approaches to resolve cultural barriers, both physician- and patient-derived, that interfere with achievement of lower blood pressure goals.

Similar Articles

Global guidelines for type 2 diabetes

Author(s): IDF Clinical Guidelines Task Force

The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men

Author(s): Lakka HM, Laaksonen DE, Lakka TA, Niskanen LK, Kumpusalo E, et al.

Computer modeling of diabetes and its complications

Author(s): The Mount Hood 4 Modeling Group

A clinical prediction rule for delirium after elective noncardiac surgery

Author(s): Marcantonio ER, Goldman L, Mangione CM, Ludwig LE, Muraca B, et al.

Blood pressure, lipids, and obesity are associated with retinopathy: the hoorn study

Author(s): van Leiden HA, Dekker JM, Moll AC, Nijpels G, Heine RJ, et al.

The UKPDS risk engine: a model for the risk of coronary heart disease in Type II diabetes (UKPDS 56)

Author(s): Stevens RJ, Kothari V, Adler AI, Stratton IM; United Kingdom Prospective Diabetes Study (UKPDS) Group

Risk factors for diabetic peripheral sensory neuropathy

Author(s): Adler AI, Boyko EJ, Ahroni JH, Stensel V, Forsberg RC, et al.

Risk factors for renal dysfunction in type 2 diabetes: U

Author(s): Retnakaran R, Cull CA, Thorne KI, Adler AI, Holman RR

Incidence and determinants of microalbuminuria in Koreans with type 2 diabetes

Author(s): Park JY, Kim HK, Chung YE, Kim SW, Hong SK, et al.

Effects of calcium-channel blockade in older patients with diabetes and systolic hypertension

Author(s): Tuomilehto J, Rastenyte D, Birkenhäger WH, Thijs L, Antikainen R, et al.

The Metabolic Syndrome is an independent predictor of cardiovascular disease in type 2 diabetic subjects

Author(s): Bonora E, Targher G, Formentini G, Calcaterra F, Lombardi S, et al.